Treat to target? Efficacy of insulin use in patients with Type 2 diabetes (T2DM) in a secondary care setting

被引：0

作者：

Muraleedharan, V. ^{[1
]}

Caddick, L. ^{[1
]}

Hardisty, C. ^{[1
]}

Tesfaye, S. ^{[1
]}

Scott, A. ^{[1
]}

机构：

[1] Royal Hallamshire Hosp, Dept Diabet, Sheffield S10 2JF, S Yorkshire, England

来源：

DIABETIC MEDICINE | 2007年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：75 / 75

页数：1

共 50 条

[1] Efficacy of metformin alone or in combination with insulin in pediatric patients with type 2 diabetes mellitus (T2DM)
Weinzimer, SA
McKnight, WJ
Murphy, K
Jawad, AF
Celona-Jacobs, N
Haque, A
Katz, LEL
DIABETES, 2001, 50 : A68 - A68
[2] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
Fonseca, Vivian
Dejager, Sylvie
Albrecht, Diego
Shirt, Lynda
Schweizer, Anja
DIABETES, 2006, 55 : A111 - A111
[3] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)
Johns, D
Herz, M
Tan, MH
Robertson, KE
Gonzalez, B
Reviriego, J
Grossman, LD
DIABETES, 2002, 51 : A102 - A102
[4] The efficacy and safety of insulin glulisine (GLU) in a Hispanic/Black population with type 2 diabetes (T2DM)
Dailey, G
Rosenstock, J
Souhami, E
Chen, Y
DIABETES, 2005, 54 : A519 - A519
[5] Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal insufficiency (RI)
Scott, Russell
Hartley, Paul
Luo, Edmund
Yee, Jacqueline
Davies, Michael
Ferreira, Juan Camilo Arjona
Williams-Herman, Debora
DIABETES, 2006, 55 : A462 - A462
[6] Exenatide in insulin treated Type 2 diabetes (T2DM) patients: a potential next step
Paisley, A. N.
Wiles, P. G.
DIABETIC MEDICINE, 2008, 25
[7] Insulin initiation in people with Type 2 diabetes (T2DM): an interface audit
Narayanan, K. R.
Thomas, R.
Kerrison, M.
Topping, L.
DIABETIC MEDICINE, 2008, 25
[8] Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM)
Garber, A. J.
Camisasca, R.-P.
Jauffret, S.
Baron, M. A.
DIABETES, 2007, 56 : A134 - A134
[9] HYPOGLYCEMIA RISK ASSOCIATED WITH BASAL INSULIN USE IN TYPE 2 DIABETES (T2DM): THE LIGHTNING STUDY
Meneghini, L.
Zhou, F. L.
Bosnyak, Z.
Berria, R.
Jimenez, J.
Bailey, T.
DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A45 - A46
[10] Persistence of the Use of Initially Prescribed Basal Insulin Therapies by People with Type 2 Diabetes (T2DM)
Gordon, Jason P.
Mcewan, Phil
Home, Philip
DIABETES, 2009, 58 : A148 - A149

← 1 2 3 4 5 →